Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Enterococcus faecalis has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Lactic acid bacteria are commonly combined in direct-fed microbial preparations, and one veterinary study paired Lactobacillus rhamnosus with Enterococcus faecalis in the same feeding trial. Both genera ferment carbohydrate to lactate and can lower luminal pH. Co-supplementation is a formulation convention in animal feed rather than a demonstrated human benefit. The animal setting limits what can be carried across.
Enterococcus faecalis ferments a range of carbohydrates and can use fructan-derived fructose released by other members of the community. Pairing a live strain with a fermentable fibre is the standard synbiotic construction. Whether it changes colonisation of this particular organism in people has not been shown. The substrate logic is sound; the outcome is not established.
Short-chain fructans reach the colon undigested and are fermented by resident lactic acid bacteria to lactate and short-chain fatty acids. Synbiotic products pair them with live strains on this basis. For enterococci specifically the fermentation capacity is strain-dependent. The pairing is a design choice, not a measured effect.
Lactate generated by lactic acid bacteria is consumed by other colonic species and converted onward to butyrate and propionate. This cross-feeding is why multi-strain products mix acid producers with organisms further down the chain. It is a well-described community process. It does not by itself establish a clinical result for any specific combination.
Yeast and bacterial probiotics are combined in some products because the yeast is unaffected by antibacterial agents that would kill the bacterial strains. The two occupy different niches and neither competes directly with the other. This is a stability and coverage argument. Read it as formulation reasoning rather than clinical evidence.
Some lactic acid bacteria, including certain enterococci, synthesise menaquinones as part of their respiratory chain. Gut bacterial menaquinone production contributes a fraction of total vitamin K status in people, though the absorbed proportion is debated. Whether a supplemental strain meaningfully adds to that is unknown. State it as a bacterial capability, not a supplemental benefit.
Certain lactic acid bacteria synthesise folate and others consume it from the medium, and which behaviour a strain shows is genotype-dependent. This matters when a strain is proposed as a folate contributor. For Enterococcus faecalis specifically the direction is not consistent across strains. Any claim here needs strain-level data that is usually absent from labels.
Enzyme and probiotic blends are sold together on the reasoning that enzymes reduce the undigested residue reaching the colon while the live organisms act on what remains. The two mechanisms do not interact directly. This is a marketing-driven pairing with limited mechanistic necessity. Nothing here rests on trial data.
Bacteria including enterococci require zinc for numerous metalloenzymes, and the host limits free zinc as a nutritional immunity strategy. Supplemental zinc alters the metal availability that shapes which organisms thrive. The direction of that effect for any one strain is not predictable. This is host-microbe metal handling, not a co-supplementation recommendation.
Lactoferrin binds free iron tightly and restricts its availability to bacteria that depend on iron scavenging. Enterococcus faecalis is unusual in that it does not require iron for growth in the way many bacteria do, which changes how it fares under iron restriction. Combining the two is therefore not neutral. The interaction is worth flagging rather than assuming benefit.
Nothing specific on file for Enterococcus faecalis. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 10 we read for Enterococcus faecalis. The full linked list is below.
8 sources behind our Enterococcus faecalis verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Read this carefully. These are 203 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Enterococcus faecalis is, not how risky it is. A report is not proof Enterococcus faecalis caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.